EVELYNNE ZATTA: Open Payments
NPI 1720780539 · BATON ROUGE, LA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$575 in 19 payments from 11 companies in 2025. Trend: 2023 $477 · 2024 $785 · 2025 $575
Food & beverage: $575
| Company | Payments | Amount |
|---|---|---|
| Bayer Healthcare Pharmaceuticals Inc. | 4 | $170 |
| Gilead Sciences, Inc. | 2 | $134 |
| AstraZeneca Pharmaceuticals LP | 3 | $57 |
| Otsuka America Pharmaceutical, Inc. | 2 | $45 |
| ABBVIE INC. | 2 | $36 |
| Daiichi Sankyo Inc. | 1 | $30 |
| Boston Scientific Corporation | 1 | $26 |
| Abbott Laboratories | 1 | $24 |
| Antares Pharma, Inc. | 1 | $18 |
| Seqirus USA Inc | 1 | $18 |
Products named: Kerendia, Yeztugo, BREZTRI, REXULTI, INJECTAFER, WATCHMAN FLX, FREESTYLE LIBRE 3, QULIPTA.
Industry payments across LA — which companies pay providers there.
